Treatment of Aggressive Thyroid Cancer

Julian Huang, Ethan James Harris, Jochen H. Lorch*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Although thyroid cancer generally has a good prognosis, there is a subset of patients for whom standard care (ie, treatment limited to surgery or surgery plus radioactive iodine) is either not appropriate because of the aggressive nature of their disease or not sufficient because of disease progression through standard treatment. Most of these tumors are in 3 groups: radioactive iodine–refractory differentiated thyroid carcinoma including poorly differentiated thyroid carcinoma anaplastic thyroid carcinoma, and progressive medullary thyroid carcinoma. Major classes of treatments in clinical development for these aggressive thyroid tumors include tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and mitogen-activated protein kinase kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)943-950
Number of pages8
JournalSurgical Pathology Clinics
Issue number4
StatePublished - Dec 2019


  • Aggressive
  • Anaplastic thyroid cancer
  • Differentiated thyroid cancer
  • Medullary thyroid cancer
  • Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Pathology and Forensic Medicine


Dive into the research topics of 'Treatment of Aggressive Thyroid Cancer'. Together they form a unique fingerprint.

Cite this